Kingsley Biopharmaceutical's CARVYKTI® Posts $710M Net Sales in Q3 2026
According to Kingsley Biopharmaceutical, CARVYKTI® generated net trade sales of approximately $710 million during the third quarter ended September 30, 2026. The product is developed by Legend Biotech, an affiliated company of Kingsley listed on Nasdaq, under a collaboration and licensing
NDAQ+0.57%
GateNews·10-13 12:41
